improved stability to degradation by g-lactamases from Gram negative bacteria (Richmond & Wotton 1976 ) which gives it an unusually broad antibacterial spectrum (O'Callaghan et al. 1976a , b, Norrby et al. 1976 . Volunteer studies as well as clinical trials have shown that cefuroxime is well tolerated, even when administered by the i.m. route, and that it is clinically effective in serious infections caused by susceptible pathogens (Foord 1976 , Norrby et al. 1977 .
The present report presents data on a large number of patients treated with cefuroxime. The pharmacokinetic part of the study includes 4 patients with CNS infections, 2 of whom were hydrocephal ic children who were given cefuroxime intraventricularly. These studies were initiated because cefuroxime is active in vitro against all pathogens commonly causing CNS infections including /-lactamase producing strains of Hmmophilus influenzae (Sykes et al. 1976 ).
PATIENTS AND METHODS

Patients
Eighty-nine patients, 36 females and 53 males, were included in the trial, a Phase II and Phase III study. Two of them were children aged 8 and 10 months, the rest were adults. The mean age of the adults was 47.6 years (range 19-87 years). All patients were hospitalized because of confirmed or suspected bacterial infections which were considered to require parenteral antibiotic treatment. Sixteen patients had 2 infections. All adult patients gave their verbal consent to participate in the study. The criteria for entering the study, as well as the treatment schedules, were approved by the Ethical Committee of the Faculty of Medicine, University of Goteborg and by the Swedish Medical Board.
Cefuroxime Treatment
The adult patients were treated with cefuroxime every 8 or 12 h in doses varying from 0.5-3 g. The doses were given as i.m. injections each I g of cefuroxime dissolved in 5 ml of saline; or as intermittent i.v. infusions via a 4 cm polyethylene catheter. In these cases cefuroxime was dissolved in 100 ml of saline and infused over 30 min followed by a rapid infusion of 100 ml of saline to wash the vessel. Intravenous bolus injections were used only in 1 patient. Indwelling catheters were changed every 48 h.
The 2 children received cefuroxime in a dose of 50 mg in 2.5 ml of saline into the cerebral ventricular system once every 24 h. External polyethylene shunts were used and cefuroxime was infused over 5 min followed by a rapid infusion of 5 ml of saline. After each intraventricular dose the catheter was clamped for 30 min to allow cefuroxime to diffuse in the ventricular system. In addition the children also received cefuroxime i.m. 15 mg/kg body weight 3 times daily, starting 24 h after the first intraventricular dose. In all patients the sites of injections or infusions were inspected 3 times daily by the responsible nurses and pain after i.m. administration as well as thrombophlebitis after i.v. infusions was recorded. Concurrent antibiotic treatment was not used in any patient.
Routine Laboratory Tests
The following tests were performed in all patients before and on every third to fifth day during and after the cefuroxime treatment: hmmoglobin, total and differential leucocyte count, quantitative estimation of platelets, erythrocyte sedimentation rate (ESR) and Coombs' direct and indirect tests; serum bilirubin, serum alkaline phosphatase, serum glutamic-oxalacetic transaminases (SGOT) serum glutamic-pyruvic transaminase (SGPT) and creatinine; urine microscopy and semiquantitative determination of blood, glucose, protein and ketones in urine.
Bacteriological Tests
Samples for bacteriological examination were taken from sites appropriate to the infections being treated. When possible, samples were taken before, every other day during and after cefuroxime treatment. Mid-stream urine samples were taken in all patients before and during the treatment and also afterwards in order to evaluate the frequency of urinary superinfections. Antibiotic susceptibility tests were performed with the paper disc technique of Ericsson & Sherris (1971) . The points used to describe susceptible (S), moderately susceptible (MS) and resistant (R) organisms when the isolates were tested against cephalosporins and cefoxitin corresponded to minimal inhibitory concentrations in solid agar dilution of <2tg/ml, 2-1 6,ug/ml and> 1 6,tg/ml respectively. Assays ofCefur-oxime Concentration In many of the patients serum concentrations and urine excretion were assayed on the second or third day of treatment. Samples were drawn before, and at 0.5, 1, 2, 3, 4, 6 and 8 h after an i.m. injection or the end of an i.v. infusion. Urinary excretion was studied in 8 h urine samples collected between 2 cefuroxime doses. For the assays, a modification of the steel cup technique described by Grove & Randall (1955) was used. Rectangular glass dishes, 30 x 30 cm, with 120 ml of Bacto Penassay agar were used. On each dish, 2 samples and 1 standard were tested, each in 2 dilutions. Six aliquots of each of the 6 dilutions thus obtained were inoculated in a randomized order (latin square design) into the steel cups. Bacillus subtilis was used as test strain and the diameters of the zones of inhibition were read after 18 h of incubation at 280C. Serum half lives (tj) were calculated graphically from the f-slope. All samples and standard solutions were tested at the same pH and protein concentrations.
RESULT
All patients included in the study had severe or moderately severe acute infections with the exception of 1 patient who was initially thought to have septicemia but later was diagnosed as a case of collagenosis. Thirty-six of the patients had concurrent diseases which might have increased their susceptibility to infections (Table 1) . Chronic alcoholism dominated the concurrent diseases and most of these patients had severe deep soft tissue infections. Tables 2 and 3 give the types of infections treated and the bacteriological data. Deep soft tissue infections dominated the material and in most of these patients Staphylococcus aureus and/or Streptococcus pyogenes, group A, were the aetiological agents isolated. About 80% of the S. aureus strains were penicillinase producing. The group of other infections consisted of 1 case of bacterial parotitis caused by Streptococcus viridans which could be isolated from pus, one case of hepatic abscess and meningitis caused by Klebsiella pneumonie, a staphylococcal pulmonary abscess, and a Salmonella gastroenteritis with arthritis.
Details of the patients with verified septicmmia are given in Table 4 . With the exception of patient No. 9 who died in septic shock before adequate antibiotic treatment was given, all these patients responded favourably to cefuroxime. Of the 4 patients who were considered improved one (No. 61 recovered from his septicemia but was found to have a sterile empyema which had to be drained. In patient No. 85, the signs of gastroenteritis and septicamia vanished but Staphylococcus san diego persisted in faces and he later developed sterile arthritis. The 4 cases of suspected septicemia included 2 young females with typical findings of gonococcal septicamia, 1 case in whom an Escherichia coli strain was isolated from blood after cefuroxime treatment and 1 case of superficial soft tissue infection caused by S. aureus in whom fever and the patient's general condition made septicaemia highly probable.
The majority of the clinical isolates were susceptible to cefuroxime (Table 2) . A comparison between cefuroxime and cefoxitin revealed no major differences in susceptibility. One Proteus vulgaris strain was moderately susceptible to cefoxitin but resistant to cefuroxime. The reverse was true for 1 strain of Hamophilis influenza, and one Bacteroidesfragilis strain was more susceptible to cefoxitin than to cefuroxime. Cephalothin seemed less effective than both cefoxitin and cefuroxime against Gram negative isolates.
Ninety-two percent of the isolates were eliminated during cefuroxime treatment, 70 % during the first 3 days, 15 % during the 4th-7th days and 7 % during th 8th-il th days. Of the 7 strains which were not eliminated, 3 were S. aureus from patients with deep soft tissue infections, 2 were Gram negative strains from wounds, I was a Klebsiella pneumonia strain in a patient with a meningitis and an hepatic abscess, and 2 were Salmonella strains that persisted in faces.
The clinical results of the cefuroxime treatment are given in Table 5 . Favourable responses were observed in 95.2% of the patients. The criteria used for considering a patient cured were absence of fever, normalized ESR, absence of leucocytosis, healing of wounds and disappearance of X-ray changes, when present. The group that was considered most improved (i.e. fulfilled most but not all of the above criteria) were mainly patients with soft tissue infections that had not healed entirely by the time that there was no further need for parenteral treatment. Also in this group were patients with lower respiratory tract infections who had persisting X-ray changes which, however, disappeared during the follow-up periods.
The therapy had no effect on the infections in 4 cases. One of these (patient No. 9 Table 4 ) was discussed above. The other patient that died had an hepatic abscess and a meningitis caused by a Klebsiella pneuimonia? strain susceptible to cefuroxime. In this patient the hepatic abscess which was considered to be the reason for the outcome of his infection, was not diagnosed until the autopsy. A third patient died during cefuroxime treatment but from cardiovascular disease, after having improved from her bronchopneumonia. The fourth patient who is listed as a failure has a suspected septicamia and a cefuroxime susceptible strain of E. coli was isolated after the end of the cefuroxime treatment. He responded later to 10 days of gentamicin treatment and the reason for the failure of the cefuroxime treatment is still obscure. In one patient, treatment had to be interrupted after the third dose because of pain reactions (see below).
Of the patients with CNS infections, the case with Klebsiella meningitis has been discussed above. The other case with meningitis was a female with a pneumococcal meningitis who responded favourably to cefuroxime. The 2 hydrocephalic children with ventriculitis both had growth of Staphylococcus epidermidis in ventricular cerebrospinal fluid (CSF). After a few intraventricular doses of cefuroxime the CSF was sterile in both patients and the clinical symptoms disappeared.
In the initial phase of the trial cefuroxime was used in various doses to evaluate the optimal regimens (Table 6 ). During the trial it became clear that in the majority of the patients a dose of 750 mg i.m. or 1000 mg i.v. 3 times daily was sufficient for a favourable clinical response and the elimination of the pathogens. The treatment times ranged from 0.5-25 days with a mean of 7 days.
Cefuroxime was well tolerated although suspected or verified adverse reactions were noted in as many as 37% of the patients (Table 7) . The dominating side effect was increased liver transaminases, which was observed in 21 patients. When these patients were studied in detail it was, however, found that in 14 patients the abnormal liver function tests could be explained by previous liver diseases and/or abnormal liver function before cefuroxime treatment (Table 8 ). The extent of the increases of SGOT and SGPT was low and in no case did the abnormal liver function tests persist during the follow-up periods.
Of the other side effects noted, nine were pains after i.m. administration of cefuroxime. Two of these patients reported severe pains and in one patient the treatment had to be stopped after the third injection. In that case the reaction was due to an injection close to the sciatic nerve and should not be ascribed to cefuroxime. In the other case, the severe pain reaction could partly be explained by the fact that the patient was highly pain sensitive. The patients complaining of moderate or slight pain reactions all described the pain as short-lived with a duration less than 1 min. The reactions were therefore considered to be due to the relatively large volumes used when cefuroxime was given by the i.m. route. No thrombophlebitis was seen in the patients that received cefuroxime i.v. A positive direct Coombs' test was noted in 2 patients, neither of whom showed any signs of hxemolysis. The only skin reaction noted was a maculopapular, confluent, itching rash on the fourth day of cefuroxime treatment of a 72-yearold female patient. This reaction was considered to be due to cefuroxime as she had no other concurrent drugs. No other allergic reactions were noted, although 8 patients had a previous history of allergic skin reactions in connection with penicillin therapy. The patients with CNS infections showed no signs of neurotoxic reactions to cefuroxime.
There were no signs of nephrotoxic reactions to cefuroxime. In 60 patients adequate serum creatinine samples were taken before, during and after the cefuroxime treatment. The serum creatinine (mg/100 ml±s.d.) in these patients was 1.22±0.28 before, 1.10±0.20 during and 1.09 ±0.17 after cefuroxime. Statistically Students' t-test showed the serum creatinine to be higher before than during or after cefuroxime (P<0.05).
This difference was considered to be due to the fact that the first samples were drawn when the patient had high fever and were often dehydrated.
The serum concentration studies revealed that high serum concentrations of cefuroxime were achieved with all the regimens used (Figs I and 2 ). 100
The calculated t4 values varied from 0.7-2.6 h with a mean of 1.4 h. The great variations could be explained by differences in renal function 50 between patients, but there were no differences that could be related to the doses given or to the route of administration. The area under the curve 25 obtained for i.m. administration in comparison to i.v. administration indicated that cefuroxime is absorbed to a large extent, if not completely, after i.m. injection. The mean 0-8 h urinary recovery 10 l was found to be 84 % of the dose (range 62-115 %).
The 2 patients with meningitis had serum and CSF concentrations determined at various times. \ In patient No. 76 with a Klebsiella meningitis (Fig 3) , the blood-CSF barrier was severely inflamed on all sampling occasions. In this patient 2 5 the ratios between cefuroxime concentrations in 2.5 serum and CSF I h after a 2 g dose were found to be 6.4 on the second day of treatment, 3.5 on the third and 2.6 on the fourth. On the fourth treatment day, samples were drawn also 5 h after the 1 dose and the serum/CSF ratio was then found to be 0.56 -a considerably higher cefuroxime concentration being found in CSF than in serum. In 0.5-i patient No. 89 (Fig 4) the meningitis improved 1 2 3 4 5 6 7 8 considerably between the 2 sampling days. In Fig 1 Serum concentrations ofcefuroxime afte i.m. that patient a lower serum/CSF ratio was found administration on the first day of cefuroxime treatment (2.5) than on the 5th day (9.6) when the blood-CSF barrier 150 was considered less inflamed. In this patient a 5 h sample was obtained only after the first dose and 100 the ratio was then 1.0. Preliminary results of studies on cefuroxime elimination from ventricular CSF in the 2 hydro-50 cephalic children who were given cefuroxime 50 mg in 5 ml intraventricularly, indicate that a peak concentration of 60 ,tg/ml is achieved about 25 I h after an intraventricular dose and that cefuroxime is eliminated with a tj of about 8 h. relatively high susceptibility of S. facalis when a low bacterial inoculum was used but this has not been verified. The pathogens isolated from the patients in this study were tested for susceptibility to cefuroxime, cephalothin and cefoxitin, the last being a cephamycin with a spectrum similar to that of cefuroxime but with better activity against B. fragilis and indole positive Proteus strains (Brumfitt et al. 1974 , Tally et al. 1975 . Cefoxitin and cefuroxime seemed equally active in these conditions with the exception of a few strains that were more susceptible to one drug than to the other. Both cefuroxime and cefoxitin were found to be more active than cephalothin against E. coli and indole negative Proteus strains, which might reflect a ,B-lactamase production by these organisms.
In a high percentage of the infections the aetiological pathogens were eliminated during cefuroxime treatment. In 70 % of the cases bacterial elimination was achieved within 3 days, indicating that cefuroxime rapidly reaches peripheral compartments in therapeutic concentrations. The cases where the bacteria were not eliminated were 5 with necrotic wound infections, 2 with Salmonella infections and 1 with an undiagnosed hepatic abscess. In all of these cases it was not surprising that the pathogens persisted.
Cefuroxime seemed to exert a low ecological pressure as only 2 cases of superinfections were noted, I funguria and 1 case of growth of P. wruginosa in a wound close to the anus. In both patients the organisms vanished after the end of cefuroxime treatment and were considered to be of no clinical importance.
Cefuroxime was clinically effective and 95 % of the patients were considered to be cured or improved. The doses of cefuroxime required for a satisfactory clinical result were low and in a majority of the patients 0.75 g i.m. or 1 g i.v. three times daily was sufficient. With these doses adequate serum and urine concentrations were achieved and because of the relatively high tj, 8 h dose intervals seemed optimal.
Cephalosporins are not normally used for the treatment of CNS infections. Clinical failures have been reported with cephalothin (Almond 1969 , Mangi et al. 1973 . With cephaloridine, better therapeutic results have been reported, but in most cases cephaloridine was given both systemically and intraventricularly (Love et al. 1970) . Despite these experiences with cephalosporins in meningitis, it was nonetheless considered clinically justified to try cefuroxime in 2 cases of severe bacterial meningitis, I caused by Klebsiella and 1 by S. pneumoniu. In the first case the patient died from meningitis as the hepatic abscess from which it derived was not diagnosed. The clinical response to therapy in the second patient was better and she was considered cured. In both patients surprisingly high concentrations of cefuroxime were assayed in CSF. The data obtained in the second patient, when concentrations were assayed during the recovery phase, indicated that an inflammatory reaction in the blood-CFS barrier permits high CSF concentrations of the drug. Cefuroxime was also given by the intraventricular route to 2 hydrocephalic children with ventriculitis. They responded favourably to therapy and high concentrations of cefuroxime were obtained in CSF. Study of the pharmacokinetics of the elimination ofcefuroxime from the CSF in these children is so far only preliminary, but indicates that cefuroxime is eliminated slowly, with a tj of about 8 h.
Although relatively frequent adverse effects were observed in the patients treated with cefuroxime, it was nonetheless considered to be a safe drug. The most commonly observed side effect was a moderate increase in liver transaminases, which in the majority of the cases could be explained by previous liver diseases in the patients. In no case did the increased transaminases cause discontinuation of the cefuroxime treatment. In all cases the liver tests normalized during or shortly after treatment. Transaminase increases have previously been reported during cephalosporin therapy (Martin & Wellman 1967 , Shemonsky et al. 1975 . The finding of a positive direct Coombs' test in 2 patients accords with what has been reported for other cephalosporins (Moltan et al. 1967) . Only 1 case of hypersensitivity reaction ascribed to cefuroxime was noted and 8 patients with a history of skin reactions during penicillin therapy did not react to cefuroxime.
The local tolerance of cefuroxime was good and only slight or moderate pains after i.m. administration were noted. These could be ascribed to the relatively large injection volumes used. No thrombophlebitis was observed after i.v. infusion. Thus, cefuroxime can easily be administered by the i.m. route which gives it an important advantage over most other cephalosporins.
As a significant number of nephrotoxic reactions have been reported after therapy with cephaloridine and cephalothin (Foord 1975) it is important to investigate every new cephalosporin for signs of nephrotoxicity. No effects by cefuroxime on the renal function of the patients in this study were noted. It should, however, be stressed that these patients were all carefully monitored to avoid overdosages and that the doses used in most cases were moderate. It cannot therefore be stated that cefuroxime is completely safe with regard to nephrotoxic reactions and it seems justified to follow the renal function of all patients treated with the drug until further clinical experience has been gained.
Summary
Cefuroxime is a new cephalosporin antibiotic with a broader antibacterial spectrum than the existing cephalosporins. This is the result of an increased stability to degradation by ,B-lactamases from Gram negative bacilli. Eighty-nine patients with acute bacterial infections were treated with cefuroxime. Clinically and bacteriologically excellent results were achieved, 95 % of the patients being cured or improved and 92 % of the isolated pathogens being eliminated during cefuroxime treatment. Various doses of cefuroxime were used, and it was concluded that an i.m. dose of 750 mg or an i.v. dose of 1000 mg 3 times daily is sufficient for a good clinical result in the majority of infections. Pharmacokinetic studies revealed that with these doses, sufficiently high serum and urine concentrations were achieved and-that with a mean half life in serum of 1.4 h, dose intervals longer than 8 h should not be necessary.
Four of the patients had CNS infections, 2 cases of bacterial meningitis and 2 hydrocephalic children with ventriculitis. In 3 of these patients cefuroxime eradicated the pathogens and clinical cures were obtained. The fourth patient died of meningitis as the focus of the infection, an hepatic abscess, was not discovered. The concentrations of cefuroxime assayed in cerebrospinal fluid from the 2 cases of meningitis indicated that very high cefuroxime concentrations are achieved when the blood-CSF barrier is inflamed. The 2 children received cefuroxime by the intraventricular route and no neurotoxic reactions were observed. Preliminary results of studies on the elimination of cefuroxime from the ventricular system of these patients indicate that the drug is eliminated slowly, with a half life of about 8 h. Elimination from the CSF is via the choroid plexus and it seems unlikely that an active transport of cefuroxime from the CSF occurs.
A considerable number of patients showed increased liver transaminases during cefuroxime treatment. In the majority of cases these findings could be explained by previous liver diseases and in all cases the liver function tests normalized during or shortly after the cefuroxime treatment. Pains at the injection sites after i.m. administration were noted in 9 patients. These reactions were considered to be due to the relatively large volumes used and not to an irritation caused by cefuroxime itself. Other side effects noted were 2 cases of positive direct Coombs' test and I case of allergic skin reaction. No nephrotoxic reactions to cefuroxime were observed.
It was concluded that cefuroxime is an important innovation. Its broader antibacterial spectrum increases the primary indications for cephalosporins and it seems clinically and bacteriologically effective without any serious side effects. In particular it may have a special role for the treatment of bacterial meningitis, partly because it seems to penetrate well through inflamed meninges and partly because it has the most favourable spectrum with respect to potential pathogens causing virulent meningitis. Professor Simon said that the figures for protein binding were cefuroxime 40%; cefazolin 87%; cephalothin 70 % and cephradine 15 %. Dr J R T Gabriel (London) asked why it had a higher concentration in the blister fluid studies if it was less closely bound to protein than the other cephalosporins.
Professor Simon said that tissue penetration and penetration into body fluids was not only dependent on protein binding but also on molecular size, molecular weight and other factors so far unexplained.
Dr A J Kuzemko (Peterborough) asked whether cefuroxime passed into normal cerebrospinal fluid.
Dr Norrby said that the question would be discussed further at the Conference, but he would not expect more than 10 % of the peak serum concentration to be achieved in a peak CSF concentration with this ,B-lactam antibiotic.
Dr J Kosmidis (Athens) said that after giving cefuroxime to a patient with normal meninges it was not detectable 3 h later in the CSF, although it had high levels in serum. Although this was only 1 case, it confirmed the expectation that the drug would not pass readily through normal meninges. He asked Dr Norrby for the cell numbers present in the 2 patients that he had described.
Dr Norrby said that the figure was about 2 x 103 in the acute phase in both patients and about 500 in the later phase in the second patient. There were marked inflammatory reactions.
Dr G F Rahim (Birmingham) asked Professor Simon whether any of his blisters became infected before complete healing, and what happened to the cefuroxime in blister fluid after 24 h.
Professor Simon said that no infection of skin blisters had occurred at any time. At the end of continuous i.v. infusion, drug concentration in skin blisters fell more slowly than in serum.
Professor Modai (Paris) had studied the passage of cefuroxime into the CSF in virulent meningitis 2 days after the beginning of the disease. Samples from 4 patients 30 min after an i.v. injection of 1 g of cefuroxime had produced levels of I ,tg/ml in CSF, but never more. Dr Norrby said that he would have expected such a result. In his first patient there was a considerably higher concentration 5 h after the dose than 1 h afterwards, and these samples were taken 1 and 5 h after the completion of the 30 min infusion, that is to say 1.5 h after its beginning. Several 3-lactam antibiotics had been claimed to have poor penetration through an intact blood-CSF barrier, but he thought that peak concentrations should be looked for at 3-5 h after dosing.
Since both of these patients had been allergic to penicillin, they were treated with cefuroxime alone.
Dr E Rubinstein (Tel-Hashomer) asked Professor Simon if his control graph was for fluid taken from normal blisters.
Professor Simon confirmed that it was. He has prepared standard curves from blister fluid taken from untreated individuals, but in studying drugs with low protein binding there was a difference between the serum standard curve and the skin blister fluid standard curve. It was important to have a special standard curve for drugs with high protein binding, because the difference in protein content could be decisive. Dr Norrby said that it had been difficult to monitor this patient closely. A higher dose of the drug would not have saved him, because they had not detected the hepatic abscess. But it might be of interest that serum levels did appear to fall slightly in the final stages.
Dr R Corocher (Verona) asked if any modification had occurred with bilirubin transport during cefuroxime treatment.
Dr Norrby had not studied the question, but certainly bilirubin was normal in all patients. They had a high proportion of narcotic and alcohol addicts which he thought accounted for the transaminase increases. Some such increase might be observed even in patients on placebo.
Dr I Nakayama (Tokyo) asked Professor Simon if he had compared i.m. injection with i.v. administration and what phases had been used in his 2-compartment model.
Professor Simon had studied i.v. administration only. The half-life in the model related to the f-phase as the slow phase of elimination.
Dr E Rubinstein (Tel-Hashomer) had had a similar experience with a method used to detect antibiotic either free or bound to protein.
Professor S Rosachino (Milan) said that since meningitis was an important disease, clinical experience should be increased beyond the 2 cases so far reported. He doubted whether the dosage of 50 mg given in hydrocephalus would be appropriate for normal meningitis sufferers.
Dr Norrby said firstly that he did not favour intrathecal administration of antibiotics, because he did not believe that the drug reached the ventricular system and stayed there. Secondly, in children with minor and major hydrocephalus, the doses were 25 and 75 mg; 50 mg was used for moderate cases. He thought these doses gave a sufficient concentration. He believed that there would be further reports on patients with meningitis, but he did not recommend routine use of cefuroxime in this condition, only further studies on the subject. 
